Savara Inc.

SVRA · Nasdaq · United States

Share price · SVRA

$4.72-0.65 (-12.10%) 3M

close as of 2026-11-18 · 24h delayed · vol 5.5M (2.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SVRA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+5.4%

    Nothing announced by SVRA that day or the session before.

  2. 6 Nov 2026+10.3%

    Nothing announced by SVRA that day or the session before.

  3. 26 Oct 2026+7.1%

    Nothing announced by SVRA that day or the session before.

  4. 23 Oct 2026-7.0%

    Nothing announced by SVRA that day or the session before.

  5. 7 Oct 2026+4.9%

    Nothing announced by SVRA that day or the session before.

  6. 2 Oct 2026-4.7%

    Nothing announced by SVRA that day or the session before.

  7. 8 Sep 2026+3.0%

    Nothing announced by SVRA that day or the session before.

  8. 13 Aug 2026-7.5%

    Nothing announced by SVRA that day or the session before.

  9. 10 Jun 2026+3.2%

    Nothing announced by SVRA that day or the session before.

  10. 30 Apr 2026+8.0%

    Nothing announced by SVRA that day or the session before.

Share of unusual movement by asset

For each asset, the share of SVRA's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
molgramostim
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—97%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GM-CSF receptor (agonist)Protein / enzyme therapeutic
Pulmonary Alveolar Proteinosis
Autoimmune Pulmonary Alveolar Proteinosis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
molgramostimPhase 3Autoimmune Pulmonary Alveolar Proteinosis
Est. primary completion 2027-06 · NCT06431776 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

22 November 2026FDA action datemolgramostimMolgramostim BLA PDUFA target action date (Priority Review, extended)
US, FDA · Savara Inc. · Source ↗

Recent

26 June 2024Topline resultmolgramostimIMPALA-2 Phase 3 (NCT04544293) meets primary endpoint
Savara Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$25M$30M+ $100M short-term inv.$43M-$42M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$22M$42M+ $131M short-term inv.$40M-$30M operating cash flowreport ↗
2026-Q1—$23M$39M+ $164M short-term inv.$37M-$33M operating cash flowreport ↗
2025-Q3—$21M$16M+ $108M short-term inv.$30M-$23M operating cash flowreport ↗
2025-Q2—$21M$17M+ $129M short-term inv.$30M-$26M operating cash flowreport ↗
2025-Q1—$19M$20M+ $153M short-term inv.$27M-$27M operating cash flowreport ↗
2024-Q3—$20M$21M+ $198M short-term inv.$24M-$23M operating cash flowreport ↗
2024-Q2—$18M$24M+ $98M short-term inv.$22M-$22M operating cash flowreport ↗
2024-Q1—$17M$17M+ $126M short-term inv.$20M-$21M operating cash flowreport ↗
2023-Q3—$14M$28M+ $141M short-term inv.$17M-$13M operating cash flowreport ↗
2023-Q2—$8.9M$23M+ $82M short-term inv.$11M-$10M operating cash flowreport ↗
2023-Q1—$8.7M$34M+ $81M short-term inv.$11M-$12M operating cash flowreport ↗
2022-Q3—$8.2M$120M+ $14M short-term inv.$10M-$8.2M operating cash flowreport ↗
2022-Q2—$6.4M$95M+ $47M short-term inv.$9.2M-$9.3M operating cash flowreport ↗
2022-Q1—$5.7M$79M+ $73M short-term inv.$8.3M-$8.4M operating cash flowreport ↗
2021-Q3$0$6.5M$45M+ $126M short-term inv.$11M-$8.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$81M$33M+ $203M short-term inv.$30M-$101M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$78M$15M+ $181M short-term inv.$24M-$89M operating cash flowreport ↗
2023-FY—$44M$27M+ $136M short-term inv.$14M-$51M operating cash flowreport ↗
2022-FY—$28M$52M+ $74M short-term inv.$9.5M-$35M operating cash flowreport ↗
2021-FY—$29M$34M+ $127M short-term inv.$11M-$40M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-24Parker Braden C. · Chief Commercial OfficerTax withholding29,323$5.07$149KForm 4
2026-07-15Lutz Robert Matthew · Chief Fin. & Operating OfficerAward / grant35,000——Form 4
2026-07-15Lutz Robert Matthew · Chief Fin. & Operating OfficerAward / grant (derivative)70,000——Form 4
2026-06-22Lowrance David L · Chief Financial OfficerOption exercise75,000$1.59$119KForm 4
2026-06-22Lowrance David L · Chief Financial OfficerTax withholding21,682$5.50$119KForm 4
2026-06-22Lowrance David L · Chief Financial OfficerOption exercise129,350$1.23$159KForm 4
2026-06-22Lowrance David L · Chief Financial OfficerTax withholding28,928$5.50$159KForm 4
2026-06-22Lowrance David L · Chief Financial OfficerOption exercise56,937$1.11$63KForm 4